TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026)
TherapeuticsMD (TXMD) posted EBITDA Margin of 99.86% for Q1 2026, up 42.54% on a QoQ basis from 173.8% in Q4 2025, and up 22609.0% year-over-year from N/an in Q1 2025.
TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD's EBITDA Margin history runs 16 years deep, the most recent figure standing at 99.86% for Q1 2026.
- Quarterly EBITDA Margin rose 22609.0% year-over-year to 99.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114.29% (up 20380.0% YoY) and the FY2025 annual result came in at 145.27%, up 20181.0% from the prior year.
- EBITDA Margin was 99.86% for Q1 2026 at TherapeuticsMD, up from 173.8% in the prior quarter.
- Across five years, EBITDA Margin topped out at 70.65% in Q4 2022 and bottomed at 4188.22% in Q2 2022.
- A 5-year average of 1054.43% and a median of 343.5% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 403527 bps — and 2023, when it jumped 365183 bps.
- TherapeuticsMD's EBITDA Margin stood at 70.65% in 2022, then slumped by 586 bps to 343.5% in 2023, then soared by 72 bps to 97.75% in 2024, then sank by 78 bps to 173.8% in 2025, then jumped by 43 bps to 99.86% in 2026.
- Business Quant data shows TXMD's EBITDA Margin at 99.86% in Q1 2026, 173.8% in Q4 2025, and 109.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | -99.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.86% |
| Dec 31, 2025 | -173.80% |
| Sep 30, 2025 | -109.95% |
| Jun 30, 2025 | -73.00% |
| Mar 31, 2025 | -325.95% |
| Dec 31, 2024 | -97.75% |
| Sep 30, 2024 | -207.31% |
| Jun 30, 2024 | -1,191.88% |
| Mar 31, 2024 | -364.86% |
| Dec 31, 2023 | -343.50% |
| Sep 30, 2023 | -3,100.00% |
| Jun 30, 2023 | -536.38% |
| Mar 31, 2023 | -634.62% |
| Dec 31, 2022 | 70.65% |
| Sep 30, 2022 | -4,024.29% |
| Jun 30, 2022 | -4,188.22% |
| Mar 31, 2022 | -2,524.60% |
| Dec 31, 2021 | -189.48% |
| Sep 30, 2021 | -157.13% |
| Jun 30, 2021 | -152.95% |